Table 2.
pCR rates in patients stratified by primary ER and HER2 status.
| ER-positive (%) | ER-negative (%) | All (%) | Univariate P value | Multivariate* | |||
|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | |||||
| HER2-0 | 21.0 | 23.2 | 21.8 | 0.635 | 0.80 | 0.31–1.29 | 0.630 |
| HER2-low | 17.7 | 31.4 | 20.6 | <0.001 | 0.47 | 0.29–0.75 | 0.002 |
| HER2-positive | 37.9 | 37.4 | 37.7 | 0.896 | 0.68 | 0.47–0.99 | 0.045 |
| All | 25.3 | 32.9 | 27.8 | <0.001 | 0.60 | 0.45–0.78 | <0.001 |
*Multivariate Cox regression model includes age, menstruation, cTNM stage, primary ER, primary PR, primary HER2, primary Ki67 statuses, NAC strategy, NAC cycle, histology type, and histological grade.
HER2 human epidermal growth factor receptor-2, HR hazard ratio, CI confidence interval, ER estrogen receptor.